Citius Pharmaceuticals reports first revenue of $3.9 mln

Citius Pharmaceuticals

13/02/2026 13:08

Overview

Biopharmaceutical firm reported first revenue of $3.9 mln from LYMPHIR launch in Q1 2026

Net loss for Q1 2026 was $8.2 mln, with basic EPS of -$0.38

Citius Oncology launched LYMPHIR for cutaneous T-cell lymphoma in December 2025

Outlook

Citius anticipates growth from international market expansion and oncology franchise development

Company plans to expand LYMPHIR access in Europe and the Middle East

Citius focuses on technology-driven platform to enhance market penetration

Result Drivers

LYMPHIR LAUNCH - Initial revenue of $3.9 mln generated from LYMPHIR sales after its launch in December 2025

AI-ENABLED PLATFORM - Citius deployed an AI-enabled commercial platform to support LYMPHIR's market penetration

INTERNATIONAL EXPANSION - Agreements with regional partners to expand LYMPHIR access through Named Patient Programs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$8.20 mln
Q1 Basic EPS
-$0.38


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $5.00, about 530.2% above its February 12 closing price of $0.79

The stock recently traded at 0 times the next 12-month earnings vs. a P/E of 3 three months ago

Press Release: ID:nPn7wjdcta

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)